Longevity Science

Rapamycin

An mTOR inhibitor originally developed as an immunosuppressant that extends lifespan in multiple animal models. Being investigated for longevity effects in dogs in the Dog Aging Project's TRIAD study.

Rapamycin (sirolimus) is a macrolide compound originally isolated from Streptomyces hygroscopicus bacteria from Easter Island (Rapa Nui — hence the name). It was developed as an immunosuppressant for organ transplant recipients and later approved as an anti-cancer agent (mTOR inhibitor).

Mechanism: mTOR Inhibition

Rapamycin inhibits mechanistic target of rapamycin (mTOR) — specifically mTORC1, a key cellular growth and metabolism regulator. mTOR integrates nutrient signals (amino acids, glucose), growth factor signals (IGF-1, insulin), and energy status to regulate:

  • Protein synthesis
  • Cell growth and proliferation
  • Autophagy (cellular self-cleaning)
  • Mitochondrial function

Inhibiting mTOR with rapamycin mimics the cellular state of nutrient restriction — autophagy is enhanced, protein synthesis is reduced, cell cycling slows. This state appears to slow cellular aging.

Evidence in Animal Models

Rapamycin is among the most replicated lifespan-extending interventions in animal models:

  • Mice: extends median lifespan 14–23% in multiple independent studies, even when started in aged animals (equivalent to age 60 in humans). Found by the National Institute on Aging Interventions Testing Program (ITP) — the gold standard preclinical longevity program.
  • C. elegans, Drosophila: consistent lifespan extension
  • Marmosets: preliminary data suggesting benefit in small primate study

TRIAD Study (Dog Aging Project)

The Dog Aging Project is conducting the TRIAD study — a randomized, placebo-controlled trial testing low-dose rapamycin (0.05–0.1 mg/kg/week) in companion dogs. Target enrollment: 580 dogs, middle-aged at enrollment (7–9 years for medium breeds). Primary endpoint: all-cause mortality over the trial period. Preliminary data from the Test of Rapamycin in Aging Dogs (TREAD) pilot showed improvement in cardiac function measures.

Current Status and Caution

Rapamycin is not approved for canine longevity use. It requires careful dosing (immune suppression risk at high doses), is prescription-only, and is being studied at doses significantly lower than transplant immunosuppression doses. Using rapamycin outside of a clinical trial framework and without veterinary oversight is not appropriate.